Skip to main content

Table 4 AEs and ADRs in the safety population in BENEFIT-Korea study

From: Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study

Age (yr)

Male

Female

AE

ADR

AE

ADR

Young, < 50

26 (7.2)

2 (0.6)

18 (14.5)

3 (2.4)

Middle-aged, 50–69

125 (12.8)

10 (1.0)

83 (16.3)

8 (1.6)

Older, ≥70

84 (15.7)

6 (1.1)

115 (18.1)

7 (1.1)

  1. Values are presented as number (%)
  2. AE adverse event, ADR adverse drug reaction